SCHOTT Pharma invests US$114M to boost sterile cartridge production in Hungary

HUNGARY— SCHOTT Pharma, a leading provider of drug containment and delivery solutions, has announced a significant investment exceeding €100 million (US$114 million) to expand its manufacturing capacity for sterile ready-to-use (RTU) cartridges at its Lukácsháza site in Hungary.

This expansion is set to create 100 new jobs, reinforcing the company’s commitment to meeting the growing demand for advanced pharmaceutical components.

RTU cartridges play a crucial role in safely storing and delivering important medications such as glucagon-like peptide-1 drugs, biologics, insulin, and hormone therapies.

These treatments are vital for managing conditions like diabetes, obesity, and various immunological disorders.

 By enhancing its production capabilities, SCHOTT Pharma aims to better support the healthcare industry with high-quality, reliable drug delivery systems.

The new facility will incorporate a fully integrated and automated production process designed to minimize manual handling.

This approach ensures the consistent production of sterile products while improving efficiency and quality control.

 Additionally, the expansion will include a state-of-the-art washing line and a steam sterilization system for cartridges.

These upgrades are intended not only to boost production but also to reduce the environmental impact of manufacturing operations, aligning with SCHOTT Pharma’s sustainability goals.

Andreas Reisse, CEO of SCHOTT Pharma, emphasized the strategic importance of this investment.

 He explained that the company is expanding its capabilities and presence in the fields of diabetes and obesity treatment to keep pace with increasing market demand.

“This is why we are investing more than $114 million in our Hungarian plant,” Reisse stated, highlighting the company’s forward-looking growth plans.

This announcement follows the opening of a new facility at the same Lukácsháza site in June 2024, which began producing high-quality prefillable glass syringes.

That earlier expansion added 120 employees and increased the site’s overall production capacity, further strengthening SCHOTT Pharma’s position in the pharmaceutical supply chain.

Eva Szabó, site manager at Lukácsháza, expressed sincere gratitude to the Hungarian Ministry of Foreign Affairs and Trade for their support during both expansion projects.

She noted that Lukácsháza is not only critical for ensuring supply security to customers in the region but also plays a key role in SCHOTT Pharma’s global growth strategy.

With this latest investment, Lukácsháza will become SCHOTT Pharma’s second site dedicated to sterile cartridge manufacturing, joining the existing facility in St. Gallen, Switzerland.

The company’s broad portfolio includes various delivery systems and drug containment solutions for injectable medications, such as prefillable glass and polymer syringes, cartridges, ampoules, and vials.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and beyond. Also, follow us on our WhatsApp channel for updates.